nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2C8—Mometasone—systemic scleroderma	0.128	0.281	CbGbCtD
Paroxetine—ABCB1—Lisinopril—systemic scleroderma	0.0587	0.128	CbGbCtD
Paroxetine—CYP2C9—Leflunomide—systemic scleroderma	0.0577	0.126	CbGbCtD
Paroxetine—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0511	0.112	CbGbCtD
Paroxetine—ABCB1—Captopril—systemic scleroderma	0.044	0.0961	CbGbCtD
Paroxetine—CYP2D6—Captopril—systemic scleroderma	0.0414	0.0905	CbGbCtD
Paroxetine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0346	0.0756	CbGbCtD
Paroxetine—ABCB1—Prednisone—systemic scleroderma	0.0277	0.0605	CbGbCtD
Paroxetine—CYP2C9—cardial valve—systemic scleroderma	0.0157	0.259	CbGeAlD
Paroxetine—ABCB1—Methotrexate—systemic scleroderma	0.0139	0.0303	CbGbCtD
Paroxetine—HTR2A—myenteric nerve plexus—systemic scleroderma	0.00739	0.122	CbGeAlD
Paroxetine—HTR2A—pulmonary artery—systemic scleroderma	0.00523	0.0865	CbGeAlD
Paroxetine—TACR1—connective tissue—systemic scleroderma	0.00318	0.0525	CbGeAlD
Paroxetine—TACR1—smooth muscle tissue—systemic scleroderma	0.00291	0.048	CbGeAlD
Paroxetine—TACR1—digestive system—systemic scleroderma	0.00229	0.0379	CbGeAlD
Paroxetine—CHRM5—skin of body—systemic scleroderma	0.00211	0.0348	CbGeAlD
Paroxetine—HTR2A—artery—systemic scleroderma	0.00194	0.0321	CbGeAlD
Paroxetine—TACR1—lung—systemic scleroderma	0.00192	0.0317	CbGeAlD
Paroxetine—HTR2A—endothelium—systemic scleroderma	0.00164	0.0271	CbGeAlD
Paroxetine—HTR2A—blood vessel—systemic scleroderma	0.00151	0.025	CbGeAlD
Paroxetine—CHRM3—smooth muscle tissue—systemic scleroderma	0.00119	0.0197	CbGeAlD
Paroxetine—SLC6A4—digestive system—systemic scleroderma	0.00106	0.0175	CbGeAlD
Paroxetine—ABCB1—blood vessel—systemic scleroderma	0.00099	0.0164	CbGeAlD
Paroxetine—SLC6A3—lung—systemic scleroderma	0.000964	0.0159	CbGeAlD
Paroxetine—CHRM3—digestive system—systemic scleroderma	0.000943	0.0156	CbGeAlD
Paroxetine—SLC6A4—lung—systemic scleroderma	0.000883	0.0146	CbGeAlD
Paroxetine—CHRM1—lung—systemic scleroderma	0.00088	0.0145	CbGeAlD
Paroxetine—CYP2B6—skin of body—systemic scleroderma	0.000857	0.0142	CbGeAlD
Paroxetine—SLC6A2—lung—systemic scleroderma	0.000777	0.0128	CbGeAlD
Paroxetine—HTR2A—connective tissue—systemic scleroderma	0.000775	0.0128	CbGeAlD
Paroxetine—HTR2A—smooth muscle tissue—systemic scleroderma	0.000709	0.0117	CbGeAlD
Paroxetine—CYP2B6—digestive system—systemic scleroderma	0.000686	0.0113	CbGeAlD
Paroxetine—CYP2C9—digestive system—systemic scleroderma	0.000679	0.0112	CbGeAlD
Paroxetine—CYP2B6—lung—systemic scleroderma	0.000573	0.00947	CbGeAlD
Paroxetine—HTR2A—digestive system—systemic scleroderma	0.000559	0.00925	CbGeAlD
Paroxetine—HTR2A—tendon—systemic scleroderma	0.000532	0.0088	CbGeAlD
Paroxetine—CYP2D6—digestive system—systemic scleroderma	0.00051	0.00842	CbGeAlD
Paroxetine—HTR2A—lung—systemic scleroderma	0.000467	0.00772	CbGeAlD
Paroxetine—ABCB1—digestive system—systemic scleroderma	0.000367	0.00606	CbGeAlD
Paroxetine—ABCB1—lung—systemic scleroderma	0.000306	0.00506	CbGeAlD
Paroxetine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000257	CcSEcCtD
Paroxetine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000257	CcSEcCtD
Paroxetine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000124	0.000257	CcSEcCtD
Paroxetine—Myocardial infarction—Prednisone—systemic scleroderma	0.000124	0.000257	CcSEcCtD
Paroxetine—Breast disorder—Methotrexate—systemic scleroderma	0.000124	0.000257	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000124	0.000256	CcSEcCtD
Paroxetine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000256	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000123	0.000256	CcSEcCtD
Paroxetine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000123	0.000255	CcSEcCtD
Paroxetine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000123	0.000255	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000255	CcSEcCtD
Paroxetine—Insomnia—Lisinopril—systemic scleroderma	0.000123	0.000254	CcSEcCtD
Paroxetine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000254	CcSEcCtD
Paroxetine—Paraesthesia—Lisinopril—systemic scleroderma	0.000122	0.000253	CcSEcCtD
Paroxetine—Vomiting—Captopril—systemic scleroderma	0.000122	0.000253	CcSEcCtD
Paroxetine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000251	CcSEcCtD
Paroxetine—Dyspnoea—Lisinopril—systemic scleroderma	0.000121	0.000251	CcSEcCtD
Paroxetine—Rash—Captopril—systemic scleroderma	0.000121	0.00025	CcSEcCtD
Paroxetine—Dermatitis—Captopril—systemic scleroderma	0.000121	0.00025	CcSEcCtD
Paroxetine—Somnolence—Lisinopril—systemic scleroderma	0.000121	0.00025	CcSEcCtD
Paroxetine—Headache—Captopril—systemic scleroderma	0.00012	0.000249	CcSEcCtD
Paroxetine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000249	CcSEcCtD
Paroxetine—Dyspepsia—Lisinopril—systemic scleroderma	0.000119	0.000248	CcSEcCtD
Paroxetine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000119	0.000247	CcSEcCtD
Paroxetine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000119	0.000247	CcSEcCtD
Paroxetine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000246	CcSEcCtD
Paroxetine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000246	CcSEcCtD
Paroxetine—Asthma—Methotrexate—systemic scleroderma	0.000118	0.000246	CcSEcCtD
Paroxetine—Infection—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000245	CcSEcCtD
Paroxetine—Decreased appetite—Lisinopril—systemic scleroderma	0.000118	0.000245	CcSEcCtD
Paroxetine—Eosinophilia—Methotrexate—systemic scleroderma	0.000117	0.000243	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000117	0.000243	CcSEcCtD
Paroxetine—Fatigue—Lisinopril—systemic scleroderma	0.000117	0.000243	CcSEcCtD
Paroxetine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000243	CcSEcCtD
Paroxetine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000242	CcSEcCtD
Paroxetine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000241	CcSEcCtD
Paroxetine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000116	0.000241	CcSEcCtD
Paroxetine—Pancreatitis—Methotrexate—systemic scleroderma	0.000116	0.000241	CcSEcCtD
Paroxetine—Constipation—Lisinopril—systemic scleroderma	0.000116	0.000241	CcSEcCtD
Paroxetine—Pain—Lisinopril—systemic scleroderma	0.000116	0.000241	CcSEcCtD
Paroxetine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000241	CcSEcCtD
Paroxetine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000239	CcSEcCtD
Paroxetine—Bradycardia—Prednisone—systemic scleroderma	0.000115	0.000239	CcSEcCtD
Paroxetine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000238	CcSEcCtD
Paroxetine—Diarrhoea—Azathioprine—systemic scleroderma	0.000114	0.000237	CcSEcCtD
Paroxetine—Haemoglobin—Prednisone—systemic scleroderma	0.000114	0.000236	CcSEcCtD
Paroxetine—Nausea—Captopril—systemic scleroderma	0.000114	0.000236	CcSEcCtD
Paroxetine—Haemorrhage—Prednisone—systemic scleroderma	0.000113	0.000235	CcSEcCtD
Paroxetine—Asthenia—Leflunomide—systemic scleroderma	0.000113	0.000235	CcSEcCtD
Paroxetine—Hallucination—Prednisone—systemic scleroderma	0.000113	0.000234	CcSEcCtD
Paroxetine—Pancytopenia—Methotrexate—systemic scleroderma	0.000112	0.000233	CcSEcCtD
Paroxetine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000112	0.000232	CcSEcCtD
Paroxetine—Pruritus—Leflunomide—systemic scleroderma	0.000112	0.000232	CcSEcCtD
Paroxetine—Connective tissue disorder—Prednisone—systemic scleroderma	0.000111	0.000231	CcSEcCtD
Paroxetine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000111	0.00023	CcSEcCtD
Paroxetine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000111	0.00023	CcSEcCtD
Paroxetine—Dysuria—Methotrexate—systemic scleroderma	0.000111	0.00023	CcSEcCtD
Paroxetine—Dizziness—Azathioprine—systemic scleroderma	0.000111	0.000229	CcSEcCtD
Paroxetine—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000109	0.000226	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000225	CcSEcCtD
Paroxetine—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000108	0.000224	CcSEcCtD
Paroxetine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000108	0.000224	CcSEcCtD
Paroxetine—Diarrhoea—Leflunomide—systemic scleroderma	0.000108	0.000224	CcSEcCtD
Paroxetine—Urticaria—Lisinopril—systemic scleroderma	0.000108	0.000223	CcSEcCtD
Paroxetine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000223	CcSEcCtD
Paroxetine—Abdominal pain—Lisinopril—systemic scleroderma	0.000107	0.000222	CcSEcCtD
Paroxetine—Body temperature increased—Lisinopril—systemic scleroderma	0.000107	0.000222	CcSEcCtD
Paroxetine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000221	CcSEcCtD
Paroxetine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000107	0.000221	CcSEcCtD
Paroxetine—Vomiting—Azathioprine—systemic scleroderma	0.000106	0.00022	CcSEcCtD
Paroxetine—Pneumonia—Methotrexate—systemic scleroderma	0.000106	0.00022	CcSEcCtD
Paroxetine—Eye disorder—Prednisone—systemic scleroderma	0.000106	0.00022	CcSEcCtD
Paroxetine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000106	0.00022	CcSEcCtD
Paroxetine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000219	CcSEcCtD
Paroxetine—Drowsiness—Methotrexate—systemic scleroderma	0.000106	0.000219	CcSEcCtD
Paroxetine—Rash—Azathioprine—systemic scleroderma	0.000105	0.000219	CcSEcCtD
Paroxetine—Dermatitis—Azathioprine—systemic scleroderma	0.000105	0.000218	CcSEcCtD
Paroxetine—Depression—Methotrexate—systemic scleroderma	0.000105	0.000218	CcSEcCtD
Paroxetine—Flushing—Prednisone—systemic scleroderma	0.000105	0.000218	CcSEcCtD
Paroxetine—Headache—Azathioprine—systemic scleroderma	0.000105	0.000217	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000105	0.000217	CcSEcCtD
Paroxetine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000217	CcSEcCtD
Paroxetine—Dizziness—Leflunomide—systemic scleroderma	0.000104	0.000217	CcSEcCtD
Paroxetine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000214	CcSEcCtD
Paroxetine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000103	0.000214	CcSEcCtD
Paroxetine—Stomatitis—Methotrexate—systemic scleroderma	0.000103	0.000213	CcSEcCtD
Paroxetine—Angiopathy—Prednisone—systemic scleroderma	0.000103	0.000213	CcSEcCtD
Paroxetine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000103	0.000213	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000213	CcSEcCtD
Paroxetine—Immune system disorder—Prednisone—systemic scleroderma	0.000102	0.000212	CcSEcCtD
Paroxetine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000211	CcSEcCtD
Paroxetine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000211	CcSEcCtD
Paroxetine—Arrhythmia—Prednisone—systemic scleroderma	0.000101	0.00021	CcSEcCtD
Paroxetine—Sweating—Methotrexate—systemic scleroderma	0.000101	0.00021	CcSEcCtD
Paroxetine—Haematuria—Methotrexate—systemic scleroderma	0.000101	0.000209	CcSEcCtD
Paroxetine—Vomiting—Leflunomide—systemic scleroderma	0.0001	0.000208	CcSEcCtD
Paroxetine—Alopecia—Prednisone—systemic scleroderma	0.0001	0.000208	CcSEcCtD
Paroxetine—Hypersensitivity—Lisinopril—systemic scleroderma	9.99e-05	0.000207	CcSEcCtD
Paroxetine—Hepatobiliary disease—Methotrexate—systemic scleroderma	9.98e-05	0.000207	CcSEcCtD
Paroxetine—Dizziness—Mycophenolic acid—systemic scleroderma	9.96e-05	0.000207	CcSEcCtD
Paroxetine—Epistaxis—Methotrexate—systemic scleroderma	9.95e-05	0.000207	CcSEcCtD
Paroxetine—Rash—Leflunomide—systemic scleroderma	9.95e-05	0.000206	CcSEcCtD
Paroxetine—Dermatitis—Leflunomide—systemic scleroderma	9.94e-05	0.000206	CcSEcCtD
Paroxetine—Mental disorder—Prednisone—systemic scleroderma	9.93e-05	0.000206	CcSEcCtD
Paroxetine—Nausea—Azathioprine—systemic scleroderma	9.93e-05	0.000206	CcSEcCtD
Paroxetine—Headache—Leflunomide—systemic scleroderma	9.89e-05	0.000205	CcSEcCtD
Paroxetine—Malnutrition—Prednisone—systemic scleroderma	9.87e-05	0.000205	CcSEcCtD
Paroxetine—Erythema—Prednisone—systemic scleroderma	9.87e-05	0.000205	CcSEcCtD
Paroxetine—Agranulocytosis—Methotrexate—systemic scleroderma	9.85e-05	0.000204	CcSEcCtD
Paroxetine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	9.79e-05	0.000203	CcSEcCtD
Paroxetine—Asthenia—Lisinopril—systemic scleroderma	9.73e-05	0.000202	CcSEcCtD
Paroxetine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	9.72e-05	0.000202	CcSEcCtD
Paroxetine—Pruritus—Lisinopril—systemic scleroderma	9.59e-05	0.000199	CcSEcCtD
Paroxetine—Vomiting—Mycophenolic acid—systemic scleroderma	9.57e-05	0.000199	CcSEcCtD
Paroxetine—Haemoglobin—Methotrexate—systemic scleroderma	9.52e-05	0.000198	CcSEcCtD
Paroxetine—Rash—Mycophenolic acid—systemic scleroderma	9.49e-05	0.000197	CcSEcCtD
Paroxetine—Dermatitis—Mycophenolic acid—systemic scleroderma	9.48e-05	0.000197	CcSEcCtD
Paroxetine—Hepatitis—Methotrexate—systemic scleroderma	9.47e-05	0.000197	CcSEcCtD
Paroxetine—Haemorrhage—Methotrexate—systemic scleroderma	9.47e-05	0.000197	CcSEcCtD
Paroxetine—Urticaria—Mycophenolate mofetil—systemic scleroderma	9.44e-05	0.000196	CcSEcCtD
Paroxetine—Headache—Mycophenolic acid—systemic scleroderma	9.43e-05	0.000196	CcSEcCtD
Paroxetine—Pharyngitis—Methotrexate—systemic scleroderma	9.4e-05	0.000195	CcSEcCtD
Paroxetine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	9.39e-05	0.000195	CcSEcCtD
Paroxetine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	9.39e-05	0.000195	CcSEcCtD
Paroxetine—Nausea—Leflunomide—systemic scleroderma	9.37e-05	0.000194	CcSEcCtD
Paroxetine—Vision blurred—Prednisone—systemic scleroderma	9.3e-05	0.000193	CcSEcCtD
Paroxetine—Diarrhoea—Lisinopril—systemic scleroderma	9.28e-05	0.000192	CcSEcCtD
Paroxetine—Ill-defined disorder—Prednisone—systemic scleroderma	9.16e-05	0.00019	CcSEcCtD
Paroxetine—Visual impairment—Methotrexate—systemic scleroderma	9.13e-05	0.000189	CcSEcCtD
Paroxetine—Anaemia—Prednisone—systemic scleroderma	9.12e-05	0.000189	CcSEcCtD
Paroxetine—Agitation—Prednisone—systemic scleroderma	9.07e-05	0.000188	CcSEcCtD
Paroxetine—Angioedema—Prednisone—systemic scleroderma	9.02e-05	0.000187	CcSEcCtD
Paroxetine—Dizziness—Lisinopril—systemic scleroderma	8.97e-05	0.000186	CcSEcCtD
Paroxetine—Erythema multiforme—Methotrexate—systemic scleroderma	8.96e-05	0.000186	CcSEcCtD
Paroxetine—Nausea—Mycophenolic acid—systemic scleroderma	8.94e-05	0.000186	CcSEcCtD
Paroxetine—Malaise—Prednisone—systemic scleroderma	8.9e-05	0.000185	CcSEcCtD
Paroxetine—Vertigo—Prednisone—systemic scleroderma	8.87e-05	0.000184	CcSEcCtD
Paroxetine—Eye disorder—Methotrexate—systemic scleroderma	8.85e-05	0.000184	CcSEcCtD
Paroxetine—Syncope—Prednisone—systemic scleroderma	8.85e-05	0.000184	CcSEcCtD
Paroxetine—Tinnitus—Methotrexate—systemic scleroderma	8.83e-05	0.000183	CcSEcCtD
Paroxetine—Cardiac disorder—Methotrexate—systemic scleroderma	8.79e-05	0.000182	CcSEcCtD
Paroxetine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	8.75e-05	0.000182	CcSEcCtD
Paroxetine—Loss of consciousness—Prednisone—systemic scleroderma	8.67e-05	0.00018	CcSEcCtD
Paroxetine—Vomiting—Lisinopril—systemic scleroderma	8.62e-05	0.000179	CcSEcCtD
Paroxetine—Angiopathy—Methotrexate—systemic scleroderma	8.59e-05	0.000178	CcSEcCtD
Paroxetine—Immune system disorder—Methotrexate—systemic scleroderma	8.56e-05	0.000178	CcSEcCtD
Paroxetine—Rash—Lisinopril—systemic scleroderma	8.55e-05	0.000177	CcSEcCtD
Paroxetine—Convulsion—Prednisone—systemic scleroderma	8.55e-05	0.000177	CcSEcCtD
Paroxetine—Dermatitis—Lisinopril—systemic scleroderma	8.54e-05	0.000177	CcSEcCtD
Paroxetine—Mediastinal disorder—Methotrexate—systemic scleroderma	8.54e-05	0.000177	CcSEcCtD
Paroxetine—Asthenia—Mycophenolate mofetil—systemic scleroderma	8.52e-05	0.000177	CcSEcCtD
Paroxetine—Hypertension—Prednisone—systemic scleroderma	8.52e-05	0.000177	CcSEcCtD
Paroxetine—Chills—Methotrexate—systemic scleroderma	8.5e-05	0.000176	CcSEcCtD
Paroxetine—Headache—Lisinopril—systemic scleroderma	8.49e-05	0.000176	CcSEcCtD
Paroxetine—Pruritus—Mycophenolate mofetil—systemic scleroderma	8.41e-05	0.000174	CcSEcCtD
Paroxetine—Arthralgia—Prednisone—systemic scleroderma	8.4e-05	0.000174	CcSEcCtD
Paroxetine—Myalgia—Prednisone—systemic scleroderma	8.4e-05	0.000174	CcSEcCtD
Paroxetine—Anxiety—Prednisone—systemic scleroderma	8.37e-05	0.000174	CcSEcCtD
Paroxetine—Alopecia—Methotrexate—systemic scleroderma	8.37e-05	0.000174	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	8.34e-05	0.000173	CcSEcCtD
Paroxetine—Discomfort—Prednisone—systemic scleroderma	8.3e-05	0.000172	CcSEcCtD
Paroxetine—Mental disorder—Methotrexate—systemic scleroderma	8.3e-05	0.000172	CcSEcCtD
Paroxetine—Erythema—Methotrexate—systemic scleroderma	8.25e-05	0.000171	CcSEcCtD
Paroxetine—Malnutrition—Methotrexate—systemic scleroderma	8.25e-05	0.000171	CcSEcCtD
Paroxetine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	8.13e-05	0.000169	CcSEcCtD
Paroxetine—Dysgeusia—Methotrexate—systemic scleroderma	8.08e-05	0.000168	CcSEcCtD
Paroxetine—Nausea—Lisinopril—systemic scleroderma	8.05e-05	0.000167	CcSEcCtD
Paroxetine—Oedema—Prednisone—systemic scleroderma	8.05e-05	0.000167	CcSEcCtD
Paroxetine—Anaphylactic shock—Prednisone—systemic scleroderma	8.05e-05	0.000167	CcSEcCtD
Paroxetine—Infection—Prednisone—systemic scleroderma	8e-05	0.000166	CcSEcCtD
Paroxetine—Back pain—Methotrexate—systemic scleroderma	7.98e-05	0.000166	CcSEcCtD
Paroxetine—Shock—Prednisone—systemic scleroderma	7.92e-05	0.000164	CcSEcCtD
Paroxetine—Nervous system disorder—Prednisone—systemic scleroderma	7.9e-05	0.000164	CcSEcCtD
Paroxetine—Tachycardia—Prednisone—systemic scleroderma	7.86e-05	0.000163	CcSEcCtD
Paroxetine—Dizziness—Mycophenolate mofetil—systemic scleroderma	7.86e-05	0.000163	CcSEcCtD
Paroxetine—Skin disorder—Prednisone—systemic scleroderma	7.82e-05	0.000162	CcSEcCtD
Paroxetine—Hyperhidrosis—Prednisone—systemic scleroderma	7.79e-05	0.000162	CcSEcCtD
Paroxetine—Vision blurred—Methotrexate—systemic scleroderma	7.77e-05	0.000161	CcSEcCtD
Paroxetine—Ill-defined disorder—Methotrexate—systemic scleroderma	7.65e-05	0.000159	CcSEcCtD
Paroxetine—Anaemia—Methotrexate—systemic scleroderma	7.62e-05	0.000158	CcSEcCtD
Paroxetine—Vomiting—Mycophenolate mofetil—systemic scleroderma	7.55e-05	0.000157	CcSEcCtD
Paroxetine—Rash—Mycophenolate mofetil—systemic scleroderma	7.49e-05	0.000155	CcSEcCtD
Paroxetine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	7.48e-05	0.000155	CcSEcCtD
Paroxetine—Headache—Mycophenolate mofetil—systemic scleroderma	7.44e-05	0.000154	CcSEcCtD
Paroxetine—Malaise—Methotrexate—systemic scleroderma	7.44e-05	0.000154	CcSEcCtD
Paroxetine—Vertigo—Methotrexate—systemic scleroderma	7.41e-05	0.000154	CcSEcCtD
Paroxetine—Leukopenia—Methotrexate—systemic scleroderma	7.38e-05	0.000153	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	7.34e-05	0.000152	CcSEcCtD
Paroxetine—Insomnia—Prednisone—systemic scleroderma	7.28e-05	0.000151	CcSEcCtD
Paroxetine—Paraesthesia—Prednisone—systemic scleroderma	7.23e-05	0.00015	CcSEcCtD
Paroxetine—Cough—Methotrexate—systemic scleroderma	7.2e-05	0.000149	CcSEcCtD
Paroxetine—Convulsion—Methotrexate—systemic scleroderma	7.15e-05	0.000148	CcSEcCtD
Paroxetine—Dyspepsia—Prednisone—systemic scleroderma	7.09e-05	0.000147	CcSEcCtD
Paroxetine—Nausea—Mycophenolate mofetil—systemic scleroderma	7.06e-05	0.000146	CcSEcCtD
Paroxetine—Chest pain—Methotrexate—systemic scleroderma	7.02e-05	0.000146	CcSEcCtD
Paroxetine—Myalgia—Methotrexate—systemic scleroderma	7.02e-05	0.000146	CcSEcCtD
Paroxetine—Arthralgia—Methotrexate—systemic scleroderma	7.02e-05	0.000146	CcSEcCtD
Paroxetine—Decreased appetite—Prednisone—systemic scleroderma	7e-05	0.000145	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	6.97e-05	0.000145	CcSEcCtD
Paroxetine—Fatigue—Prednisone—systemic scleroderma	6.94e-05	0.000144	CcSEcCtD
Paroxetine—Discomfort—Methotrexate—systemic scleroderma	6.94e-05	0.000144	CcSEcCtD
Paroxetine—Constipation—Prednisone—systemic scleroderma	6.89e-05	0.000143	CcSEcCtD
Paroxetine—Confusional state—Methotrexate—systemic scleroderma	6.79e-05	0.000141	CcSEcCtD
Paroxetine—Anaphylactic shock—Methotrexate—systemic scleroderma	6.73e-05	0.00014	CcSEcCtD
Paroxetine—Infection—Methotrexate—systemic scleroderma	6.69e-05	0.000139	CcSEcCtD
Paroxetine—Feeling abnormal—Prednisone—systemic scleroderma	6.64e-05	0.000138	CcSEcCtD
Paroxetine—Nervous system disorder—Methotrexate—systemic scleroderma	6.6e-05	0.000137	CcSEcCtD
Paroxetine—Thrombocytopenia—Methotrexate—systemic scleroderma	6.59e-05	0.000137	CcSEcCtD
Paroxetine—Gastrointestinal pain—Prednisone—systemic scleroderma	6.59e-05	0.000137	CcSEcCtD
Paroxetine—Skin disorder—Methotrexate—systemic scleroderma	6.54e-05	0.000136	CcSEcCtD
Paroxetine—Hyperhidrosis—Methotrexate—systemic scleroderma	6.51e-05	0.000135	CcSEcCtD
Paroxetine—Urticaria—Prednisone—systemic scleroderma	6.4e-05	0.000133	CcSEcCtD
Paroxetine—Body temperature increased—Prednisone—systemic scleroderma	6.37e-05	0.000132	CcSEcCtD
Paroxetine—Abdominal pain—Prednisone—systemic scleroderma	6.37e-05	0.000132	CcSEcCtD
Paroxetine—Hypotension—Methotrexate—systemic scleroderma	6.29e-05	0.00013	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	6.13e-05	0.000127	CcSEcCtD
Paroxetine—Insomnia—Methotrexate—systemic scleroderma	6.09e-05	0.000126	CcSEcCtD
Paroxetine—Paraesthesia—Methotrexate—systemic scleroderma	6.04e-05	0.000125	CcSEcCtD
Paroxetine—Dyspnoea—Methotrexate—systemic scleroderma	6e-05	0.000124	CcSEcCtD
Paroxetine—Somnolence—Methotrexate—systemic scleroderma	5.98e-05	0.000124	CcSEcCtD
Paroxetine—Hypersensitivity—Prednisone—systemic scleroderma	5.93e-05	0.000123	CcSEcCtD
Paroxetine—Dyspepsia—Methotrexate—systemic scleroderma	5.92e-05	0.000123	CcSEcCtD
Paroxetine—Decreased appetite—Methotrexate—systemic scleroderma	5.85e-05	0.000121	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.81e-05	0.000121	CcSEcCtD
Paroxetine—Fatigue—Methotrexate—systemic scleroderma	5.8e-05	0.00012	CcSEcCtD
Paroxetine—Asthenia—Prednisone—systemic scleroderma	5.78e-05	0.00012	CcSEcCtD
Paroxetine—Pain—Methotrexate—systemic scleroderma	5.76e-05	0.000119	CcSEcCtD
Paroxetine—Pruritus—Prednisone—systemic scleroderma	5.7e-05	0.000118	CcSEcCtD
Paroxetine—Feeling abnormal—Methotrexate—systemic scleroderma	5.55e-05	0.000115	CcSEcCtD
Paroxetine—Diarrhoea—Prednisone—systemic scleroderma	5.51e-05	0.000114	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.5e-05	0.000114	CcSEcCtD
Paroxetine—Urticaria—Methotrexate—systemic scleroderma	5.35e-05	0.000111	CcSEcCtD
Paroxetine—Dizziness—Prednisone—systemic scleroderma	5.33e-05	0.00011	CcSEcCtD
Paroxetine—Body temperature increased—Methotrexate—systemic scleroderma	5.32e-05	0.00011	CcSEcCtD
Paroxetine—Abdominal pain—Methotrexate—systemic scleroderma	5.32e-05	0.00011	CcSEcCtD
Paroxetine—Vomiting—Prednisone—systemic scleroderma	5.12e-05	0.000106	CcSEcCtD
Paroxetine—Rash—Prednisone—systemic scleroderma	5.08e-05	0.000105	CcSEcCtD
Paroxetine—Dermatitis—Prednisone—systemic scleroderma	5.07e-05	0.000105	CcSEcCtD
Paroxetine—Headache—Prednisone—systemic scleroderma	5.05e-05	0.000105	CcSEcCtD
Paroxetine—Hypersensitivity—Methotrexate—systemic scleroderma	4.96e-05	0.000103	CcSEcCtD
Paroxetine—Asthenia—Methotrexate—systemic scleroderma	4.83e-05	0.0001	CcSEcCtD
Paroxetine—Nausea—Prednisone—systemic scleroderma	4.78e-05	9.92e-05	CcSEcCtD
Paroxetine—Pruritus—Methotrexate—systemic scleroderma	4.76e-05	9.88e-05	CcSEcCtD
Paroxetine—Diarrhoea—Methotrexate—systemic scleroderma	4.6e-05	9.55e-05	CcSEcCtD
Paroxetine—Dizziness—Methotrexate—systemic scleroderma	4.45e-05	9.23e-05	CcSEcCtD
Paroxetine—Vomiting—Methotrexate—systemic scleroderma	4.28e-05	8.88e-05	CcSEcCtD
Paroxetine—Rash—Methotrexate—systemic scleroderma	4.24e-05	8.8e-05	CcSEcCtD
Paroxetine—Dermatitis—Methotrexate—systemic scleroderma	4.24e-05	8.8e-05	CcSEcCtD
Paroxetine—Headache—Methotrexate—systemic scleroderma	4.22e-05	8.75e-05	CcSEcCtD
Paroxetine—Nausea—Methotrexate—systemic scleroderma	4e-05	8.29e-05	CcSEcCtD
